Fritz Leutmezer

5.9k total citations · 1 hit paper
126 papers, 3.1k citations indexed

About

Fritz Leutmezer is a scholar working on Pathology and Forensic Medicine, Neurology and Rheumatology. According to data from OpenAlex, Fritz Leutmezer has authored 126 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Pathology and Forensic Medicine, 50 papers in Neurology and 22 papers in Rheumatology. Recurrent topics in Fritz Leutmezer's work include Multiple Sclerosis Research Studies (83 papers), Peripheral Neuropathies and Disorders (25 papers) and Polyomavirus and related diseases (20 papers). Fritz Leutmezer is often cited by papers focused on Multiple Sclerosis Research Studies (83 papers), Peripheral Neuropathies and Disorders (25 papers) and Polyomavirus and related diseases (20 papers). Fritz Leutmezer collaborates with scholars based in Austria, Germany and United States. Fritz Leutmezer's co-authors include Christoph Baumgartner, Stefanie Lurger, Thomas Berger, Paulus Rommer, Wolfgang Serles, Assunta Dal‐Bianco, Hans Lassmann, Ekaterina Pataraia, Siegfried Trattnig and Klaus Pötzelberger and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Brain.

In The Last Decade

Fritz Leutmezer

115 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging

2016 313 citations Assunta Dal‐Bianco, Michael Weber et al. Acta Neuropathologica profile →

Peers

Countries citing papers authored by Fritz Leutmezer

Since Specialization

Citations

This map shows the geographic impact of Fritz Leutmezer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fritz Leutmezer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fritz Leutmezer more than expected).

Fields of papers citing papers by Fritz Leutmezer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fritz Leutmezer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fritz Leutmezer. The network helps show where Fritz Leutmezer may publish in the future.

Co-authorship network of co-authors of Fritz Leutmezer

This figure shows the co-authorship network connecting the top 25 collaborators of Fritz Leutmezer. A scholar is included among the top collaborators of Fritz Leutmezer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fritz Leutmezer. Fritz Leutmezer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association Between Retinal Layer Atrophy With Clinical and Radiologic Progression in People With Relapsing Multiple Sclerosis 2025 ·Neurology ·Gabriel Bsteh, Harald Hegen, Nik Krajnc, (unknown), Lukas Haider, Barbara Kornek, Fritz Leutmezer, Stefan Macher, (unknown), Markus Ponleitner, Paulus Rommer, (unknown), Karin Zebenholzer, Gudrun Zulehner, Tobias Zrzavy, Franziska Di Pauli, Berthold Pemp, Thomas Berger	0
2	Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR) 2025 ·Journal of Neurology ·(unknown), (unknown), Markus Ponleitner, Nik Krajnc, Tobias Zrzavy, Gabriel Bsteh, Paulus Rommer, Barbara Kornek, Christian Enzinger, Franziska Di Pauli, Jörg Kraus, Michael Guger, Fritz Leutmezer, Thomas Berger, (unknown)	0
3	Early intensive versus escalation treatment in patients with relapsing–remitting multiple sclerosis in Austria 2024 ·Journal of Neurology ·Michael Guger, Christian Enzinger, Fritz Leutmezer, Franziska Di Pauli, Jörg Kraus, (unknown), Erich Kvas, Thomas Berger, (unknown)	2
4	Disability progression is a question of definition—A methodological reappraisal by example of primary progressive multiple sclerosis 2024 ·Multiple Sclerosis and Related Disorders ·Gabriel Bsteh, (unknown), Nik Krajnc, (unknown), Anke Salmen, (unknown), Fritz Leutmezer, Paulus Rommer, Franziska Di Pauli, (unknown), Thomas Berger, Harald Hegen, Robert Hoepner	1
5	Non‐interventional, prospective, observational study on spasticity‐associated symptom control with nabiximols as add‐on therapy in patients with multiple sclerosis spasticity in Austria 2023 ·Brain and Behavior ·Michael Guger, (unknown), Fritz Leutmezer	4
6	Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing–remitting multiple sclerosis in Austria 2023 ·Journal of Neurology ·Michael Guger, Christian Enzinger, Fritz Leutmezer, Franziska Di Pauli, Jörg Kraus, (unknown), Erich Kvas, Thomas Berger, (unknown)	2
7	Myeloid cell iron uptake pathways and paramagnetic rim formation in multiple sclerosis 2023 ·Acta Neuropathologica ·(unknown), Nik Krajnc, Assunta Dal‐Bianco, (unknown), Tobias Zrzavy, (unknown), Gregor Kasprian, Claudia E. Weber, Francesco Pezzini, Fritz Leutmezer, Paulus Rommer, Gabriel Bsteh, Michael Platten, Achim Gass, Thomas Berger, Philipp Eisele, Roberta Magliozzi, Lucas Schirmer, Simon Hametner	22
8	Retinal layer thickness predicts disability accumulation in early relapsing multiple sclerosis 2023 ·European Journal of Neurology ·Gabriel Bsteh, Harald Hegen, Patrick Altmann, Michael Auer, Klaus Berek, Franziska Di Pauli, Lukas Haider, Barbara Kornek, Nik Krajnc, Fritz Leutmezer, Stefan Macher, Paulus Rommer, (unknown), Karin Zebenholzer, Gudrun Zulehner, Florian Deisenhammer, Berthold Pemp, Thomas Berger	9
9	Retinal Layer Thinning After Optic Neuritis Is Associated With Future Relapse Remission in Relapsing Multiple Sclerosis 2022 ·Neurology ·Gabriel Bsteh, Nik Krajnc, (unknown), Patrick Altmann, Barbara Kornek, Fritz Leutmezer, Stefan Macher, Christoph Mitsch, (unknown), Paulus Rommer, Gudrun Zulehner, Berthold Pemp, Thomas Berger, (unknown)	3
10	Long‐term outcome after COVID‐19 infection in multiple sclerosis: A nation‐wide multicenter matched‐control study 2022 ·European Journal of Neurology ·Gabriel Bsteh, (unknown), (unknown), (unknown), (unknown), Nik Krajnc, Franziska Di Pauli, Harald Hegen, (unknown), Fritz Leutmezer, Peter Wipfler, Gudrun Zulehner, Michael Guger, Christian Enzinger, Thomas Berger, (unknown)	20
11	Comparing humoral immune response to SARS‐CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study 2022 ·European Journal of Neurology ·Gabriel Bsteh, Harald Hegen, (unknown), Nik Krajnc, Fritz Leutmezer, Franziska Di Pauli, Barbara Kornek, Paulus Rommer, Gudrun Zulehner, (unknown), (unknown), (unknown), (unknown), Michael Winklehner, Florian Deisenhammer, Michael Guger, Romana Höftberger, Thomas Berger	15
12	Impact of vaccination on COVID‐19 outcome in multiple sclerosis 2022 ·European Journal of Neurology ·Gabriel Bsteh, (unknown), (unknown), Harald Hegen, Franziska Di Pauli, (unknown), Fritz Leutmezer, (unknown), Nik Krajnc, Gudrun Zulehner, (unknown), Paulus Rommer, Peter Wipfler, Michael Guger, Christian Enzinger, Thomas Berger, (unknown)	12
13	Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry 2021 ·Journal of Neurology ·Michael Guger, Christian Enzinger, Fritz Leutmezer, Franziska Di Pauli, Jörg Kraus, (unknown), Erich Kvas, Thomas Berger, (unknown)	12
14	Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study 2021 ·Multiple Sclerosis Journal ·Gabriel Bsteh, (unknown), (unknown), Harald Hegen, (unknown), Fritz Leutmezer, Franziska Di Pauli, (unknown), (unknown), Gudrun Zulehner, Paulus Rommer, Peter Wipfler, Michael Guger, Romana Höftberger, Christian Enzinger, Thomas Berger	22
15	The Smartphone App haMSter for Tracking Patient-Reported Outcomes in People With Multiple Sclerosis: Protocol for a Pilot Study 2021 ·JMIR Research Protocols ·Patrick Altmann, (unknown), Fritz Leutmezer, Markus Ponleitner, (unknown), Tobias Zrzavy, Gudrun Zulehner, Barbara Kornek, Rupert Lanzenberger, Klaus Berek, Paulus Rommer, Thomas Berger, Gabriel Bsteh	3
16	Validation of inter-eye difference thresholds in optical coherence tomography for identification of optic neuritis in multiple sclerosis 2020 ·Multiple Sclerosis and Related Disorders ·Gabriel Bsteh, Harald Hegen, Patrick Altmann, Michael Auer, Klaus Berek, Anne Zinganell, Franziska Di Pauli, Paulus Rommer, Florian Deisenhammer, Fritz Leutmezer, Thomas Berger	25
17	Real‐life use of oral disease‐modifying treatments in Austria 2019 ·Acta Neurologica Scandinavica ·Michael Guger, Christian Enzinger, Fritz Leutmezer, Jörg Kraus, (unknown), Erich Kvas, Thomas Berger, (unknown)	9
18	Do elevated autoantibodies in patients with multiple sclerosis matter? 2018 ·Acta Neurologica Scandinavica ·Assunta Dal‐Bianco, (unknown), Paulus Rommer, Michael Weber, Patrick Altmann, Jörg Kraus, Fritz Leutmezer, (unknown)	6
19	Real‐life clinical use of natalizumab and fingolimod in Austria 2017 ·Acta Neurologica Scandinavica ·Michael Guger, Christian Enzinger, Fritz Leutmezer, Jörg Kraus, (unknown), Erich Kvas, Thomas Berger	22
20	Autonomic symptoms during epileptic seizures 2001 ·Epileptic Disorders ·Christoph Baumgartner, Stefanie Lurger, Fritz Leutmezer	151

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact